Component

Cutaneous, respiratory and cardiovascular responses in atopic adults

Experimental model, exposure and limitations remain on each linked record.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The 26-adult crossover study found no significant cutaneous, respiratory or cardiovascular difference between tartrazine and placebo.

    Experimental context and source evidence
    dose
    Tartrazine 35 mg versus placebo
    duration
    Acute challenge; exact observation period not in abstract
    evidence_access
    Primary PubMed abstract; unrecovered method details explicitly retained.
    evidence_scope
    literature_reviewed; source-specific experimental curation
    experimental_model
    26 atopic adults with rhinitis, asthma, urticaria or NSAID-related reactions
    limitations
    Small study with no significant group response does not rule out rare individual intolerance.
    nutrient_topic
    Tartrazine food-colorant chapter; nutrient, drug and peptide interactions retain their models and limits. · Tartrazine
    organism
    26 atopic adults with rhinitis, asthma, urticaria or NSAID-related reactions
    plain_language
    The 26-adult crossover study found no significant cutaneous, respiratory or cardiovascular difference between tartrazine and placebo.
    primary_references
    Safety of ingestion of yellow tartrazine by double-blind placebo controlled challenge in 26 atopic adults. (2010). https://pubmed.ncbi.nlm.nih.gov/20106580/ DOI: 10.1016/j.aller.2009.09.009
    route
    Oral administration
    tissue
    Double-blind placebo-controlled crossover challenge

    Tartrazine: mechanisms, molecular forms and cross-actor connections (2026-09-20) · lines 336–345

    Original AI-assisted curation of eighteen primary studies. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 26 atopic adults with rhinitis, asthma, urticaria or NSAID-related reactions · source_derived_draft · unverified_draft

    ## tartrazine-atopic-null The 26-adult crossover study found no significant cutaneous, respiratory or cardiovascular difference between tartrazine and placebo. Model/species: 26 atopic adults with rhinitis, asthma, urticaria or NSAID-related reactions Tissue: Double-blind placebo-controlled crossover challenge Exposure: Tartrazine 35 mg versus placebo Route: Oral administration Duration: Acute challenge; exact observation period not in abstract Limits: Small study with no significant group response does not rule out rare individual intolerance. Primary reference: Safety of ingestion of yellow tartrazine by double-blind placebo controlled challenge in 26 atopic adults. (2010). https://pubmed.ncbi.nlm.nih.gov/20106580/ DOI: 10.1016/j.aller.2009.09.009 Access: Primary PubMed abstract; unrecovered method details explicitly retained.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards